The impact of high versus standard enteral protein provision on functional recovery following intensive care admission: Protocol for a pre-planned secondary Bayesian analysis of the PRECISe trial

• Main Authors: Heuts, Samuel, de Heer, Pieter, Gabrio, Andrea, Bels, Julia L.M., Lee, Zheng-Yii, Stoppe, Christian, van Kuijk, Sander, Beishuizen, Albertus, de Bie-Dekker, Ashley, Fraipont, Vincent, Lamote, Stoffel, Ledoux, Didier, Scheeren, Clarissa, De Waele, Elisabeth, van Zanten, Arthur, Mesotten, Dieter, van de Poll, Marcel C.G.
• Format: Article
• Published: Elsevier 2024
• Subjects: R Medicine (General)
• Online Access: http://eprints.um.edu.my/44868/; https://doi.org/10.1016/j.clnesp.2023.10.040
• Institution: Universiti Malaya

Background: The PRECISe trial is a pragmatic, multicenter randomized controlled trial that evaluates the effect of high versus standard enteral protein provision on functional recovery in adult, mechanically ventilated critically ill patients. The current protocol presents the rationale and analysis plan for an evaluation of the primary and secondary outcomes under the Bayesian framework, with an emphasis on clinically important effect sizes. Methods: This protocol was drafted in agreement with the ROBUST-statement, and is submitted for publication before database lock and primary data analysis. The primary outcome is health-related quality of life as measured by the EQ-5D-5L health utility score and is longitudinally assessed. Secondary outcomes comprise the 6-min walking test and handgrip strength over the entire follow-up period (longitudinal analyses), and 60-day mortality, duration of mechanical ventilation, and EQ-5D-5L health utility scores at 30, 90 and 180 days (cross-sectional). All analyses will primarily be performed under weakly informative priors. When available, informative priors elicited from contemporary literature will also be incorporated under alternative scenarios. In all other cases, objectively formulated skeptical and enthusiastic priors will be defined to assess the robustness of our results. Relevant identified subgroups were: patients with acute kidney injury, severe multi-organ failure and patients with or without sepsis. Results will be presented as absolute risk differences, mean differences, and odds ratios, with accompanying 95 credible intervals. Posterior probabilities will be estimated for clinically important benefit and harm. Discussion: The proposed secondary, pre-planned Bayesian analysis of the PRECISe trial will provide additional information on the effects of high protein on functional and clinical outcomes in critically ill patients, such as probabilistic interpretation, probabilities of clinically important effect sizes, and the integration of prior evidence. As such, it will complement the interpretation of the primary outcome as well as several secondary and subgroup analyses. © 2023 The Author(s)